Eosinophil depletion: Why 'good enough' isn't enough anymore

Written by The Life Science Feed Editorial Team · Published 6 September 2026 · Edited by Mara Voss

Eosinophil-driven diseases represent a spectrum of chronic inflammatory conditions, from severe asthma and atopic dermatitis to eosinophilic gastroenteritis and hypereosinophilic syndrome. For years, therapeutic strategies aimed at reducing eosinophil counts were considered sufficient. But emerging understanding of disease pathogenesis suggests that a more aggressive approach to eosinophil depletion is not merely beneficial, but often necessary for meaningful clinical improvement.

KEY TAKEAWAYS

- The Pivot: Achieving near-complete eosinophil depletion, rather than just reduction, is increasingly recognized as the therapeutic goal in many eosinophil-driven diseases.
- The Data: Specific numeric results are not provided, but the principle emphasizes a profound reduction in eosinophil counts to below detection limits or to very low absolute numbers.
- The Action: Clinicians should consider therapies capable of achieving profound eosinophil suppression in patients with severe eosinophil-driven conditions, moving beyond symptomatic control to target the underlying inflammatory driver.

Eosinophils, a type of granulocyte, are key effector cells in allergic inflammation and host defense against parasites. While their presence is physiological, their uncontrolled accumulation and activation drive pathology in a range of chronic inflammatory disorders. These conditions are characterized by tissue infiltration of eosinophils, leading to organ damage, impaired function, and significant morbidity. The traditional view often focused on managing symptoms and reducing eosinophil counts to a 'normal' range, but this approach frequently left patients with residual disease activity and ongoing tissue damage.

The pathogenesis of eosinophil-driven diseases is complex, involving intricate interactions between eosinophils, other immune cells, and structural cells. Interleukin-5 (IL-5) is a cytokine that plays a central role in the growth, differentiation, recruitment, activation, and survival of eosinophils. Elevated IL-5 levels are consistently found in patients with severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). This understanding has led to the development of targeted therapies designed to interfere with the IL-5 pathway, either by blocking IL-5 itself or its receptor.

The Mechanism of Eosinophil-Driven Pathology

Eosinophils contribute to tissue damage through several mechanisms. Upon activation, they release a potent cocktail of cytotoxic granule proteins, including major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil-derived

neurotoxin (EDN), and eosinophil peroxidase (EPO). These proteins are directly toxic to epithelial cells, nerve cells, and other tissues, contributing to inflammation, fibrosis, and organ dysfunction. For example, in the airways of patients with severe eosinophilic asthma, MBP can cause desquamation of bronchial epithelium, leading to airway hyperresponsiveness and remodeling. Similarly, in eosinophilic esophagitis, persistent eosinophilic inflammation leads to esophageal strictures and dysphagia.

Beyond direct cytotoxicity, eosinophils also produce a wide array of cytokines, chemokines, and lipid mediators that perpetuate inflammation. They can act as antigen-presenting cells, influencing T-cell responses, and contribute to tissue remodeling by releasing growth factors like transforming growth factor-beta (TGF-β). This role means that simply reducing their numbers may not be enough to halt the inflammatory cascade or reverse established tissue damage. Residual eosinophils, even at seemingly low levels, can continue to drive pathological processes, necessitating a more profound therapeutic intervention.

Defining 'Near-Complete' Depletion

The concept of 'near-complete' eosinophil depletion moves beyond achieving a normal peripheral blood eosinophil count. It implies reducing eosinophil levels to below detection limits or to absolute counts that are physiologically insignificant, often below 50 cells/µL, and ideally even lower. This profound reduction aims to eliminate the cellular drivers of inflammation and prevent further tissue damage. The rationale is that if the primary effector cell is virtually absent, the downstream inflammatory consequences are significantly mitigated, leading to better clinical outcomes and potentially disease modification.

Achieving this level of depletion requires highly effective targeted therapies. Conventional treatments, such as corticosteroids, can reduce eosinophil counts but often come with significant side effects and may not achieve the sustained, profound depletion required for severe cases. But newer biologic agents, particularly those targeting the IL-5 pathway, have demonstrated the capacity to achieve these very low eosinophil levels. These agents include monoclonal antibodies that bind to IL-5 (e.g., mepolizumab, reslizumab) or to the IL-5 receptor alpha subunit (e.g., benralizumab), thereby preventing IL-5 from interacting with its receptor on the eosinophil surface.

Clinical Impact of Profound Depletion

The clinical benefits of near-complete eosinophil depletion are evident across several eosinophil-driven conditions. In severe eosinophilic asthma, achieving profound reductions in blood eosinophil counts has been associated with significant improvements in lung function, reductions in exacerbation rates, and decreased reliance on oral corticosteroids. Patients who achieve the lowest eosinophil counts often experience the most dramatic clinical responses. This is not merely a statistical correlation; it reflects a direct mechanistic link between the absence of the effector cell and the resolution of its pathological effects.

For conditions like EGPA and HES, which can involve multiple organ systems and carry significant morbidity and mortality, profound eosinophil depletion is even more important for preventing irreversible organ damage. These diseases often present with severe symptoms affecting the heart, lungs, skin, and nervous system. In these contexts, therapies that achieve near-complete eosinophil suppression have shown the ability to induce remission, prevent relapses, and improve organ function. The goal here is not just symptom control, but preventing irreversible organ damage and

improving long-term prognosis. For a deeper understanding of managing these complex conditions, clinicians might consult resources like the Oxford Handbook of Clinical Immunology and Allergy.

Challenges and Considerations

While the benefits of near-complete eosinophil depletion are clear, several challenges remain. Identifying which patients will benefit most from such aggressive depletion strategies is important for optimizing patient outcomes. Biomarkers, particularly peripheral blood eosinophil counts, are useful but not always perfectly predictive of tissue eosinophilia or treatment response. Some patients may have significant tissue eosinophilia despite relatively normal blood counts, highlighting the need for a comprehensive diagnostic approach that may include tissue biopsies.

The long-term safety of sustained, profound eosinophil depletion is another consideration. Eosinophils do have physiological roles, particularly in host defense against parasitic infections. While clinical trials have generally shown a good safety profile for anti-IL-5 therapies, vigilance for potential opportunistic infections, especially in regions where parasitic infections are endemic, is warranted. But the clinical experience to date suggests that the benefits of disease control in severe eosinophil-driven conditions generally outweigh these theoretical risks, particularly when considering the morbidity associated with uncontrolled disease or chronic corticosteroid use.

Another aspect to consider is the cost-effectiveness of these advanced biologic therapies. While highly effective, they represent a significant financial investment for healthcare systems. Therefore, careful patient selection and monitoring of treatment response are essential to ensure that these therapies are used in the patients most likely to derive substantial benefit. The ongoing development of new biomarkers and predictive tools will help refine patient selection and optimize treatment strategies, ensuring that profound eosinophil depletion is targeted to those who truly need it.

Future Directions in Eosinophil-Targeted Therapy

The success of IL-5 targeted therapies has opened avenues for further research into eosinophil biology and novel therapeutic targets. Understanding the precise mechanisms by which eosinophils contribute to different disease phenotypes could lead to more personalized treatment approaches. For instance, exploring other cytokines involved in eosinophil activation or survival, or targeting specific eosinophil receptors, could offer additional therapeutic options for patients who do not respond optimally to IL-5 pathway blockade. The field is also exploring whether early intervention with profound eosinophil depletion can prevent disease progression or even induce long-term remission, particularly in newly diagnosed patients with severe disease. This proactive approach could fundamentally alter the natural history of these chronic conditions. For example, understanding how allergen immunotherapy modifies disease trajectory in allergic rhinitis provides a parallel for how early, targeted intervention can alter long-term outcomes in other eosinophil-driven allergic diseases.

The shift towards near-complete eosinophil depletion represents a maturation in our understanding and management of eosinophil-driven diseases. It moves beyond simply alleviating symptoms to fundamentally altering the underlying inflammatory process. This aggressive approach, enabled by targeted biologic therapies, offers patients with severe and refractory conditions a chance at meaningful disease control and improved quality of life, reducing the burden of chronic inflammation and its associated complications. The ongoing challenge is to ensure these therapies are applied judiciously and effectively to the patients who stand to gain the most.

CLINICAL IMPLICATIONS

The drive for near-complete eosinophil depletion marks a significant evolution in managing eosinophil-driven diseases. For clinicians, this means re-evaluating what constitutes an adequate response to therapy. Simply reducing eosinophil counts to within a 'normal' range may no longer be sufficient for patients with severe, refractory conditions, particularly when tissue damage is ongoing.

This change in approach necessitates a more aggressive therapeutic strategy, often involving biologic agents that specifically target the IL-5 pathway. GPs and specialists alike should be aware of the potential for these therapies to achieve profound eosinophil suppression, offering a level of disease control previously unattainable with conventional treatments. It is about moving beyond symptomatic management to addressing the root cellular driver of inflammation.

The implications extend to patient selection and monitoring. Identifying patients who will benefit most from these advanced therapies requires careful assessment, potentially including tissue biopsies in addition to blood eosinophil counts. While generally safe, the long-term effects of sustained eosinophil absence warrant continued vigilance, particularly regarding host defense mechanisms.

This focus on near-complete depletion highlights the importance of precision medicine in chronic inflammatory diseases. It challenges us to consider not just whether a drug works, but how completely it addresses the underlying pathology, thereby offering patients a better chance at long-term remission and improved quality of life.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Shomali W, Gotlib J. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(5):946-968. doi:10.1002/ajh.27287
2. 2. Siddiqui S, Bachert C, Bjermer L, et al. Eosinophils and tissue remodeling: Relevance to airway disease. J Allergy Clin Immunol. 2023;152(4):841-857. doi:10.1016/j.jaci.2023.06.005
3. 3. Chung KF, Dixey P, Abubakar-Waziri H, et al. Characteristics, phenotypes, mechanisms and management of severe asthma. Chin Med J (Engl). 2022;135(10):1141-1155. doi:10.1097/CM9.0000000000001990
4. 4. Maspero J, Adir Y, Al-Ahmad M, et al. Type 2 inflammation in asthma and other airway diseases. ERJ Open Res. 2022;8(3). doi:10.1183/23120541.00576-2021
5. 5. Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Ann Rheum Dis. 2022;81(3):309-314. doi:10.1136/annrheumdis-2021-221794
6. 6. David B, Bafadhel M, Koenderman L, De Soyza A. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021;76(2):188-195. doi:10.1136/thoraxjnl-2020-215167

LICENCE & RIGHTS